Takeda Pharmaceuticals Announces FDA Acceptance of Biologics Licence Application for ENTYVIO®

Takeda Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics Licence Application (BLA) for the subcutaneous (SC) administration of ENTYVIO® (vedolizumab) as a maintenance therapy for adults with moderately to severely active Crohn's disease (CD) after undergoing induction therapy with ENTYVIO intravenous (IV).

Vedolizumab is a biologic therapy available in both intravenous (IV) and subcutaneous (SC) formulations. Vedolizumab is a humanised monoclonal antibody designed to specifically block the alpha4beta7 integrin. 

The BLA application for the subcutaneous administration of ENTYVIO for the treatment of adults with moderately to severely active CD is based on data from a Phase 3 clinical trial called VISIBLE 2. 

This trial evaluated the safety and effectiveness of an SC formulation of ENTYVIO as maintenance therapy in comparison to a placebo in 409 adult patients with moderately to severely active CD who had achieved a clinical response* at week 6 after receiving two doses of open-label vedolizumab IV therapy at weeks 0 and 2.

This action inhibits the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), which plays a role in inflammatory processes within the intestines. Notably, it does not affect vascular cell adhesion molecule 1 (VCAM-1).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!